Abstract
Evidence obtained in multiple experimental models has revealed that cardiac ‘conditioning’ strategies — including ischaemic preconditioning, postconditioning, remote conditioning and administration of pharmacological conditioning mimetics — are profoundly protective and significantly attenuate myocardial ischaemia-reperfusion injury. As a result, there is considerable interest in translating these cardioprotective paradigms from the laboratory to patients. However, the majority of studies investigating conditioning-induced cardioprotection have utilized healthy adult animals devoid of the risk factors and co-morbidities associated with cardiovascular disease and acute myocardial infarction. The aim of this article is to summarize the growing consensus that two well established risk factors, aging and diabetes mellitus, may render the heart refractory to the favourable effects of myocardial conditioning, and discuss the clinical implications of a loss in efficacy of cardiac conditioning paradigms in these patient populations.
Similar content being viewed by others
References
American Heart Association-International Cardiovascular Disease Statistics. 2009 update [online]. Available from URL: http://americanheart.org/downloadable/heart/1236204012112INTL.pdf [Accessed 2010 Oct 12]
Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics: 2010 update — a report from the American Heart Association. Circulation 2010; 121: e46–215
Bolli R, Becker L, Gross G, et al. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004; 95: 125–34
Hausenloy DJ, Baxter G, Bell R, et al. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol 2010; 677–86
Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985; 76: 1713–9
Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121–35
Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124–36
Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol 2003; 285: H579–88
Przyklenk K, Bauer B, Ovize M, et al. Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993; 87: 893–9
Granfeldt A, Lefer DJ, Vinten-Johansen J. Protective ischaemia in patients: preconditioning and postconditioning. Cardiovasc Res 2009; 83: 234–46
Hausenloy DJ, Yellon DM. Preconditioning and post-conditioning: underlying mechanisms and clinical application. Atherosclerosis 2009; 204: 334–41
Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech 2010; 3: 35–8
Peart JN, Headrick JP. Clinical cardioprotection and the value of conditioning responses. Am J Physiol Heart Circ Physiol 2009; 296: H1705–20
Mewton N, Ivanes F, Cour M, et al. Postconditioning: from experimental proof to clinical concept. Dis Model Mech 2010; 3: 39–44
Hausenloy DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 2007; 370: 575–9
Thielmann M, Kottenberg E, Boengler K, et al. Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 2010; 105: 657–64
Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010; 375: 727–34
Przyklenk K, Kloner RA. Ischemic preconditioning: exploring the paradox. Prog Cardiovasc Dis 1998; 40: 517–47
Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 1113–51
Cohen MV, Downey JM. Ischemic postconditioning: from receptor to end-effector. Antioxid Redox Signal 2011; 14: 821–31
Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004; 61: 448–60
Przyklenk K, Maynard M, Whittaker P. First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with preconditioning. Am J Physiol 2006; 291: H2008–12
Cohen MV, Downey JM. Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 2008; 103: 203–15
Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008; 88: 581–609
Yang X, Cohen MV, Downey JM. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc Drugs Ther 2010; 24: 225–34
Nishihara M, Miura T, Miki T, et al. Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol 2007; 43: 564–70
Terashima Y, Sato T, Yano T, et al. Roles of phospho-GSK-3beta in myocardial protection afforded by activation of the mitochondrial K ATP channel. J Mol Cell Cardiol 2010; 49: 762–70
Juhaszova M, Zorov DB, Yaniv Y, et al. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009; 104: 1240–52
Miura T, Tanno M, Sato T. Mitochondrial kinase signalling pathways in myocardial protection from ischaemia/reperfusion-induced necrosis. Cardiovasc Res 2010; 88:7–15
Murphy E, Steenbergen C. What makes the mitochondria a killer? Can we condition them to be less destructive? Biochim Biophys Acta. Epub 2010 Sept 15
Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 2007; 1767: 1007–31
Javadov SA, Clarke S, Das M, et al. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003; 549: 513–24
Vinten-Johansen J, Zhao ZQ, Zatta AJ, et al. Postconditioning: a new link in nature’s armor against myocardial ischemia-reperfusion injury. Basic Res Cardiol 2005; 100: 295–310
Vinten-Johansen J, Granfeldt A, Mykytenko J, et al. The multi-dimensional physiological responses to post-conditioning. Antioxid Redox Signal 2011; 14: 791–810
Skyschally A, van Caster P, Boengler K, et al. Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 2009; 104: 15–8
Lacerda L, Somers S, Opie LH, et al. Ischaemic post-conditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 2009; 84: 201–8
Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 2009; 47: 32–40
Whittaker P, Przyklenk K. Reduction of infarct size in vivo with ischemic preconditioning: mathematical evidence for protection via non-ischemic tissue. Basic Res Cardiol 1994; 89: 6–15
Przyklenk K, Darling CE, Dickson EW, et al. Cardioprotection ‘outside the box’: the evolving paradigm of remote preconditioning. Basic Res Cardiol 2003; 98: 149–57
Gho BC, Schoemaker RG, van den Doel MA, et al. Myocardial protection by brief ischemia in noncardiac tissue. Circulation 1996; 94: 2193–200
Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation 1997; 96: 1641–6
Schmidt MR, Smerup M, Konstantinov IE, et al. Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning. Am J Physiol Heart Circ Physiol 2007; 292: H1883–90
Kerendi F, Kin H, Halkos ME, et al. Remote post-conditioning: brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol 2005; 100: 404–12
Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res 2008; 79: 377–86
Kharbanda RK, Nielsen TT, Redington AN. Translation of remote ischaemic preconditioning into clinical practice. Lancet 2009; 374: 1557–65
Shimizu M, Tropak M, Diaz RJ, et al. Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection. Clin Sci (Lond) 2009; 117: 191–200
Li J, Xuan W, Yan R, et al. Remote preconditioning provides potent cardioprotection via PI3k/Akt activation and is associated with nuclear accumulation of beta-catenin. Clin Sci (Lond) 2011; 120: 451–62
Weber C. Far from the heart: receptor cross-talk in remote conditioning. Nat Med 2010; 16: 760–2
Lim SY, Yellon DM, Hausenloy DJ. The neural and humoral pathways in remote limb ischemic preconditioning. Basic Res Cardiol 2010; 105: 651–5
Burley DS, Baxter GF. Pharmacological targets revealed by myocardial postconditioning. Curr Opin Pharmacol 2009; 9: 177–88
Peart JN, Gross GJ. Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors. Am J Physiol Heart Circ Physiol 2003; 285: H81–9
Peart JN, Gross GJ. Cross-talk between adenosine and opioid receptors. Drug News Perspect 2005; 18: 237–42
Peart JN, Gross GJ. Exogenous activation of delta- and kappa-opioid receptors affords cardioprotection in isolated murine heart. Basic Res Cardiol 2004; 99: 29–37
Peart JN, Gross ER, Gross GJ. Opioid-induced preconditioning: recent advances and future perspectives. Vascul Pharmacol 2005; 42: 211–8
Zaugg M, Lucchinetti E, Uecker M, et al. Anaesthetics and cardiac preconditioning, part I: signalling and cytoprotective mechanisms. Br J Anaesth 2003; 91: 551–65
Zaugg M, Lucchinetti E, Garcia C, et al. Anaesthetics and cardiac preconditioning, part II: clinical implications. Br J Anaesth 2003; 91: 566–76
Tanaka K, Ludwig LM, Kersten JR, et al. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 2004; 100: 707–21
Riess ML, Stowe DF, Warltier DC. Cardiac pharmacological preconditioning with volatile anesthetics: from bench to bedside? Am J Physiol Heart Circ Physiol 2004; 286: H1603–7
Gomez L, Thibault H, Gharib A, et al. Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2007; 293: H1654–61
Lim SY, Davidson SM, Hausenloy DJ, et al. Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res 2007; 75: 530–5
Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009; 104: 189–202
Gomez L, Li B, Mewton N, et al. Inhibition of mitochondrial permeability transition pore opening: translation to patients. Cardiovasc Res 2009; 83: 226–33
Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and post-conditioning. Pharmacol Rev 2007; 59: 418–58
Miki T, Miura T, Tsuchida A, et al. Cardioprotective mechanism of ischemic preconditioning is impaired by post-infarct ventricular remodeling through angiotensin II type 1 receptor activation. Circulation 2000; 102: 458–63
Miki T, Miura T, Tanno M, et al. Interruption of signal transduction between G protein and PKC-epsilon underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled hearts. Mol Cell Biochem 2003; 247: 185–93
Song X, Li G, Vaage J, et al. Effects of sex, gonadectomy, and oestrogen substitution on ischaemic preconditioning and ischaemia-reperfusion injury in mice. Acta Physiol Scand 2003; 177: 459–66
Murphy E, Steenbergen C. Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury. Cardiovasc Res 2007; 75: 478–86
Lagranha CJ, Deschamps A, Aponte A, et al. Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females. Circ Res 2010; 106: 1681–91
World Health Organization. Health topics [online]. Available from URL: http://www.who.int/topics/ageing/en/ [Accessed 2010 Oct 15]
McKay CR, Rich MW, Vlietstra RE, et al. Executive summary: pivotal research in cardiovascular syndromes in the elderly. Am J Geriatr Cardiol 2000; 9: 243–50
Swynghedauw B, Besse S, Assayag P, et al. Molecular and cellular biology of the senescent hypertrophied and failing heart. Am J Cardiol 1995; 76: 2D–7D
Roka F, Freissmuth M, Nanoff C. G protein-dependent signalling and ageing. Exp Gerontol 2000; 35: 133–43
Korzick DH, Holiman DA, Boluyt MO, et al. Diminished alpha1-adrenergic-mediated contraction and translocation of PKC in senescent rat heart. Am J Physiol Heart Circ Physiol 2001; 281: H581–9
Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises, part I: aging arteries — a ‘set up’ for vascular disease. Circulation 2003; 107: 139–46
Naito Z, Takashi E, Xu G, et al. Different influences of hyperglycemic duration on phosphorylated extracellular signal-regulated kinase 1/2 in rat heart. Exp Mol Pathol 2003; 74: 23–32
Taylor RP, Starnes JW. Age, cell signalling and cardioprotection. Acta Physiol Scand 2003; 178: 107–16
Hunter JC, Korzick DH. Age- and sex-dependent alterations in protein kinase C (PKC) and extracellular regulated kinase 1/2 (ERK1/2) in rat myocardium. Mech Ageing Dev 2005; 126: 535–50
Juhaszova M, Rabuel C, Zorov DB, et al. Protection in the aged heart: preventing the heart-break of old age? Cardiovasc Res 2005; 66: 233–44
Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 2007; 56: 127–36
Ekladous D, Mehdi MZ, Costa M, et al. Tissue- and fibre-specific modifications of insulin-signalling molecules in cardiac and skeletal muscle of diabetic rats. Clin Exp Pharmacol Physiol 2008; 35: 971–8
Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res 2009; 83: 247–61
Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal 2010; 12: 537–77
Long P, Nguyen Q, Thurow C, et al. Caloric restriction restores the cardioprotective effect of preconditioning in the rat heart. Mech Ageing Dev 2002; 123: 1411–3
Schulman D, Latchman DS, Yellon DM. Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2001; 281: H1630–6
Abete P, Calabrese C, Ferrara N, et al. Exercise training restores ischemic preconditioning in the aging heart. J Am Coll Cardiol 2000; 36: 643–50
Abete P, Ferrara N, Cioppa A, et al. Preconditioning does not prevent postischemic dysfunction in aging heart. J Am Coll Cardiol 1996; 27: 1777–86
Abete P, Testa G, Ferrara N, et al. Cardioprotective effect of ischemic preconditioning is preserved in food-restricted senescent rats. Am J Physiol Heart Circ Physiol 2002; 282: H1978–87
Fenton RA, Dickson EW, Meyer TE, et al. Aging reduces the cardioprotective effect of ischemic preconditioning in the rat heart. J Mol Cell Cardiol 2000; 32: 1371–5
Tani M, Honma Y, Hasegawa H, et al. Direct activation of mitochondrial K(ATP) channels mimics preconditioning but protein kinase C activation is less effective in middle-aged rat hearts. Cardiovasc Res 2001; 49: 56–68
Tani M, Honma Y, Takayama M, et al. Loss of protection by hypoxic preconditioning in aging Fischer 344 rat hearts related to myocardial glycogen content and Na+ imbalance. Cardiovasc Res 1999; 41: 594–602
Tani M, Suganuma Y, Hasegawa H, et al. Changes in ischemic tolerance and effects of ischemic preconditioning in middle-aged rat hearts. Circulation 1997; 95: 2559–66
Abete P, Cacciatore F, Testa G, et al. Ischemic preconditioning in the aging heart: from bench to bedside. Ageing Res Rev 2010; 9: 153–62
Boengler K, Konietzka I, Buechert A, et al. Loss of ischemic preconditioning’s cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. Am J Physiol Heart Circ Physiol 2007; 292: H1764–9
Boengler K, Buechert A, Heinen Y, et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008; 102: 131–5
Przyklenk K, Maynard M, Darling CE, et al. Aging mouse hearts are refractory to infarct size reduction with post-conditioning. J Am Coll Cardiol 2008; 51: 1393–8
Przyklenk K, Maynard M, Greiner D, et al. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal 2011; 781–90
Willems L, Ashton KJ, Headrick JP. Adenosine-mediated cardioprotection in the aging myocardium. Cardiovasc Res 2005; 66: 245–55
Mio Y, Bienengraeber MW, Marinovic J, et al. Age-related attenuation of isoflurane preconditioning in human atrial cardiomyocytes: roles for mitochondrial respiration and sarcolemmal adenosine triphosphate-sensitive potassium channel activity. Anesthesiology 2008; 108: 612–20
Peart JN, Gross GJ. Chronic exposure to morphine produces a marked cardioprotective phenotype in aged mouse hearts. Exp Gerontol 2004; 39: 1021–6
Sniecinski R, Liu H. Reduced efficacy of volatile anesthetic preconditioning with advanced age in isolated rat myocardium. Anesthesiology 2004; 100: 589–97
Zhu J, Rebecchi MJ, Tan M, et al. Age-associated differences in activation of Akt/GSK-3beta signaling pathways and inhibition of mitochondrial permeability transition pore opening in the rat heart. J Gerontol A Biol Sci Med Sci 2010; 65: 611–9
Yin Z, Gao H, Wang H, et al. Ischaemic post-conditioning protects both adult and aged Sprague-Dawley rat heart from ischaemia-reperfusion injury through the phosphatidylinositol 3-kinase-AKT and glycogen synthase kinase-3beta pathways. Clin Exp Pharmacol Physiol 2009; 36: 756–63
Shinmura K, Nagai M, Tamaki K, et al. Gender and aging do not impair opioid-induced late preconditioning in rats. Basic Res Cardiol 2004; 99: 46–55
McCully JD, Uematsu M, Parker RA, et al. Adenosine-enhanced ischemic preconditioning provides enhanced cardioprotection in the aged heart. Ann Thorac Surg 1998; 66: 2037–43
Przyklenk K, Li G, Whittaker P. No loss in the in vivo efficacy of ischemic preconditioning in middle-aged and old rabbits. J Am Coll Cardiol 2001; 38: 1741–7
Przyklenk K, Li G, Simkhovich BZ, et al. Mechanisms of myocardial ischemic preconditioning are age related: PKC-epsilon does not play a requisite role in old rabbits. J Appl Physiol 2003; 95: 2563–9
Burns PG, Krunkenkamp IB, Calderone CA, et al. Is the preconditioning response conserved in senescent myocardium? Ann Thorac Surg 1996; 61: 925–9
Peart JN, Headrick JP. Sustained cardioprotection: exploring unconventional modalities. Vascul Pharmacol 2008; 49: 63–70
Peart JN, See Hoe L, Gross GJ, et al. Sustained ligand-activated preconditioning via (delta)-opioid receptors. J Pharmacol Exp Ther 2011; 336: 274–81
Korzick DH, Kostyak JC, Hunter JC, et al. Local delivery of PKCepsilon-activating peptide mimics ischemic preconditioning in aged hearts through GSK-3beta but not F1-ATPase inactivation. Am J Physiol Heart Circ Physiol 2007; 293: H2056–63
Kersten JR, Toller WG, Tessmer JP, et al. Hyperglycemia reduces coronary collateral blood flow through a nitric oxide-mediated mechanism. Am J Physiol Heart Circ Physiol 2001; 281: H2097–104
Kristiansen SB, Lofgren B, Stottrup NB, et al. Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 2004; 47: 1716–21
Kersten JR, Toller WG, Gross ER, et al. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000; 278: H1218–24
Tsang A, Hausenloy DJ, Mocanu MM, et al. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005; 54: 2360–4
Xu G, Takashi E, Kudo M, et al. Contradictory effects of short- and long-term hyperglycemias on ischemic injury of myocardium via intracellular signaling pathway. Exp Mol Pathol 2004; 76: 57–65
Bouhidel O, Pons S, Souktani R, et al. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol 2008; 295: H1580–6
Wagner C, Kloeting I, Strasser RH, et al. Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3beta. J Cardiovasc Pharmacol 2008; 52: 430–7
Huhn R, Heinen A, Weber NC, et al. Hyperglycaemia blocks sevoflurane-induced postconditioning in the rat heart in vivo: cardioprotection can be restored by blocking the mitochondrial permeability transition pore. Br J Anaesth 2008; 100: 465–71
Raphael J, Gozal Y, Navot N, et al. Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling. J Cardiovasc Pharmacol 2010; 55: 348–57
Huisamen B. Protein kinase B in the diabetic heart. Mol Cell Biochem 2003; 249: 31–8
Mocanu MM, Field DC, Yellon DM. A potential role for PTEN in the diabetic heart. Cardiovasc Drugs Ther 2006; 20: 319–21
Huhn R, Heinen A, Hollmann MW, et al. Cyclosporine A administered during reperfusion fails to restore cardioprotection in prediabetic Zucker obese rats in vivo. Nutr Metab Cardiovasc Dis 2010; 20: 706–12
Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4: a clinical correlate to preconditioning? Circulation 1995; 91: 37–45
Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits infarct size: a role for ischemic preconditioning. Circulation 1995; 91: 291–7
Ishihara M, Sato H, Tateishi H, et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol 1997; 30: 970–5
Kloner RA, Shook T, Antman EM, et al. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation 1998; 97: 1042–5
Jenkins DP, Pugsley WB, Alkhulaifi AM, et al. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart 1997; 77: 314–8
Ghosh S, Galinanes M. Protection of the human heart with ischemic preconditioning during cardiac surgery: role of cardiopulmonary bypass. J Thorac Cardiovasc Surg 2003; 126: 133–42
Kloner RA, Speakman MT, Przyklenk K. Ischemic preconditioning: a plea for rationally targeted clinical trials. Cardiovasc Res 2002; 55: 526–33
Rezkalla SH, Kloner RA. Ischemic preconditioning and preinfarction angina in the clinical arena. Nat Clin Pract Cardiovasc Med 2004; 1: 96–102
Rezkalla SH, Kloner RA. Preconditioning in humans. Heart Fail Rev 2007; 12: 201–6
Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473–81
Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005; 112: 2143–8
Darling CE, Solari PB, Smith CS, et al. ‘Postconditioning’ the human heart: multiple balloon inflations during primary angioplasty may confer cardioprotection. Basic Res Cardiol 2007; 102: 274–8
Yang XC, Liu Y, Wang LF, et al. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J Invasive Cardiol 2007; 19: 424–30
Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation 2008; 117: 1037–44
Ebrahim Z, Yellon DM, Baxter GF. Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension. Exp Gerontol 2007; 42: 807–14
Ishihara M, Inoue I, Kawagoe T, et al. Ischaemic preconditioning effect of prodromal angina pectoris is lost in patients with prior myocardial infarction. Heart 2006; 92: 973–4
Ungi I, Ungi T, Ruzsa Z, et al. Hypercholesterolemia attenuates the anti-ischemic effect of preconditioning during coronary angioplasty. Chest 2005; 128: 1623–8
Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 2001; 33: 1897–918
Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998; 31: 950–6
Jimenez-Navarro M, Gomez-Doblas JJ, Alonso-Briales J, et al. Does angina the week before protect against first myocardial infarction in elderly patients? Am J Cardiol 2001; 87: 11–5
Kloner RA, Przyklenk K, Shook T, et al. Protection conferred by preinfarct angina is manifest in the aged heart: evidence from the TIMI 4 Trial. J Thromb Thrombolysis 1998; 6: 89–92
Ishihara M, Inoue I, Kawagoe T, et al. Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 2001; 38: 1007–11
Abete P, Ferrara N, Cacciatore F, et al. Angina-induced protection against myocardial infarction in adult and elderly patients: a loss of preconditioning mechanism in the aging heart? J Am Coll Cardiol 1997; 30: 947–54
Ishihara M, Sato H, Tateishi H, et al. Beneficial effect of prodromal angina pectoris is lost in elderly patients with acute myocardial infarction. Am Heart J 2000; 139: 881–8
Wu ZK, Pehkonen E, Laurikka J, et al. The protective effects of preconditioning decline in aged patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 122:972–8
Acknowledgements
No sources of funding were used to assist in the preparation of this article. The author has no conflicts of interest that are directly relevant to the content of this article. The author gratefully acknowledges Peter Whittaker, PhD, for critical discussions during the preparation of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Przyklenk, K. Efficacy of Cardioprotective ‘Conditioning’ Strategies in Aging and Diabetic Cohorts. Drugs Aging 28, 331–343 (2011). https://doi.org/10.2165/11587190-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11587190-000000000-00000